Insights

European expansion Oncopeptides is actively commercializing Pepaxti in Europe with new distribution partnerships in the pipeline for South Korea, the Middle East and Africa, presenting opportunities to align regional market entry strategies, co-promotion options, and local regulatory engagement.

Partnership leverage Recent distribution agreement with Salus Group in Central and Eastern Europe indicates receptiveness to partnership-driven sales models; explore similar distributor collaborations, channel partnerships, and regional access programs to accelerate Pepaxti adoption.

Clinical momentum Ongoing data presentation at major hematology congresses and established clinical utility for Pepaxti in relapsed refractory multiple myeloma signal continued demand; identify opportunities to bundle diagnostics, companion studies, or expanded indications with payer-ready value propositions.

Financial runway Strong early 2026 revenue growth and a recent SEK 200 million rights issue provide liquidity for market expansion, enabling targeted sales campaigns, regional market access initiatives, and co-funded clinical research collaborations to support uptake.

R&D funnel Pipeline development on two proprietary platforms PDC and SPiKE suggests upsell potential to strategic partners; pursue licensing, co-development, or milestone-driven deals around upcoming candidates to diversify revenue streams beyond Pepaxti.

Similar companies to Oncopeptides AB (publ)

Oncopeptides AB (publ) Tech Stack

Oncopeptides AB (publ) uses 8 technology products and services including iCIMS, oEmbed, Veeva Systems, and more. Explore Oncopeptides AB (publ)'s tech stack below.

iCIMS
Applicant Tracking Systems
oEmbed
Dev Tools
Veeva Systems
IT Infrastructure & Operations Management
Microsoft Word
Office Suites
Priority Hints
Performance
Cloudflare Bot Management
Security
Google Analytics
Web Analytics
Facebook
Widgets

Media & News

Oncopeptides AB (publ)'s Email Address Formats

Oncopeptides AB (publ) uses at least 2 format(s):

Oncopeptides AB (publ) Email Formats	Example	Percentage
First.Last@oncopeptides.com	John.Doe@oncopeptides.com	91%
FirstLast@oncopeptides.com	JohnDoe@oncopeptides.com	4%
First.Middle.Last@oncopeptides.com	John.Michael.Doe@oncopeptides.com	3%
LastF@oncopeptides.com	DoeJ@oncopeptides.com	2%
First.Last@oncopeptides.se	John.Doe@oncopeptides.se	96%
First.Middle.Last@oncopeptides.se	John.Michael.Doe@oncopeptides.se	3%
First-Last@oncopeptides.se	John-Doe@oncopeptides.se	1%

Frequently Asked Questions

Where is Oncopeptides AB (publ)'s headquarters located?

Oncopeptides AB (publ)'s main headquarters is located at 46 Luntmakargatan Stockholm, Stockholm 111 37 Sweden. The company has employees across 3 continents, including EuropeNorth AmericaAsia.

What is Oncopeptides AB (publ)'s phone number?

You can contact Oncopeptides AB (publ)'s main corporate office by phone at

+46-70-569-5****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Oncopeptides AB (publ)'s official website and social media links?

Oncopeptides AB (publ)'s official website is oncopeptides.com and has social profiles on LinkedIn.

What is Oncopeptides AB (publ)'s NAICS code?

Oncopeptides AB (publ)'s NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Oncopeptides AB (publ) have currently?

As of June 2026, Oncopeptides AB (publ) has approximately 85 employees across 3 continents, including EuropeNorth AmericaAsia. Key team members include Chief Executive Officer: S. H.Chief Operating Officer: E. N.Chief Financial Officer: H. B.. Explore Oncopeptides AB (publ)'s employee directory with LeadIQ.

What industry does Oncopeptides AB (publ) belong to?

Oncopeptides AB (publ) operates in the Pharmaceutical Manufacturing industry.

What technology does Oncopeptides AB (publ) use?

Oncopeptides AB (publ)'s tech stack includes iCIMSoEmbedVeeva SystemsMicrosoft WordPriority HintsCloudflare Bot ManagementGoogle AnalyticsFacebook.

What is Oncopeptides AB (publ)'s email format?

Oncopeptides AB (publ)'s email format typically follows the pattern of First.Last@oncopeptides.com. Find more Oncopeptides AB (publ) email formats with LeadIQ.

When was Oncopeptides AB (publ) founded?

Oncopeptides AB (publ) was founded in 2000.

Oncopeptides AB (publ)

Q: How many employees does Oncopeptides AB (publ) have currently?

Oncopeptides AB (publ) has approximately 85 employees.

Q: What technology does Oncopeptides AB (publ) use?

Oncopeptides AB (publ)'s tech stack includes Medidata, PRINCE2, Veeva Systems, Adobe Creative Suite, LinkedIn.

Q: What is Oncopeptides AB (publ)'s NAICS code?

Oncopeptides AB (publ)'s NAICS code is 3254 (Pharmaceutical and Medicine Manufacturing).

Pharmaceutical ManufacturingStockholm, Sweden51-200 Employees

Oncopeptides AB is a Swedish pharmaceutical company focused on research, development, and commercialization of targeted cancer therapies. It employs proprietary drug-conjugate platforms to deliver cytotoxic agents directly into cancer cells, aiming to improve treatment specificity for hard-to-treat malignancies. The company’s flagship therapy, Pepaxti, is being commercialized in Europe, with partnerships in place for distribution in several regions, and ongoing development of additional candidates based on its PDC and SPiKE platforms. Headquartered in Stockholm, the firm operates across Europe with a presence in multiple countries and markets its products to healthcare providers and partners involved in cancer care.